Battery Ventures / Battery Global Advisors, LLC
Battery Ventures makes majority growth investment in Phigenics
Summary: A Business Wire paid press release republished by Yahoo Finance says Phigenics announced a strategic majority-growth investment from Battery Ventures. The release says the partnership is intended to support Phigenics' tech-enabled water-management platform, new and existing products, and expansion into new markets.
Why it matters: The update may matter to due-diligence readers as a source-attributed Battery private-transaction and industrial-technology signal, while the release should not be read as independent evidence of water-safety outcomes, product efficacy, customer adoption, valuation, fund exposure, expected returns, or investment merit.
Summary
A Business Wire paid press release republished by Yahoo Finance says Phigenics announced a strategic majority-growth investment from Battery Ventures. The release describes Phigenics as a Warrenville, Illinois-based provider of tech-enabled water-management programs, accredited laboratory testing, monitoring equipment, and related software.
The release says Battery will partner with CEO Mark Crockett and the existing management team, and that Battery General Partner Zack Smotherman and Battery Principal Max Kaye will join Phigenics’ board. This draft treats those statements as company press-release facts, not as independent validation of Phigenics’ product efficacy, public-health outcomes, customer adoption, regulatory quality, valuation, Battery fund exposure, returns, or investment merit.
Why it matters
For due-diligence readers, the useful signal is that Battery is named as the majority-growth investor in a water-management and testing business with healthcare and facility-safety exposure. Private-transaction announcements can help readers track a manager’s sector cadence, control/growth-investment activity, operating themes, and board-level involvement.
The signal is bounded by source posture. A paid/company press release can support the announced investor role, broad company description, management partnership, board additions, and stated growth intent, but it should not be treated as independent proof that the products reduce disease risk, that customer adoption is durable, that regulatory outcomes are improved, or that the investment has any particular return or suitability profile.
Source notes
- Business Wire paid press release via Yahoo Finance: https://finance.yahoo.com/healthcare/articles/phigenics-announces-majority-growth-investment-130000459.html
- SEC AdviserInfo firm summary for identity context: https://adviserinfo.sec.gov/firm/summary/158508
- Source posture: paid/company press release republished by Yahoo Finance. Attribute Phigenics’ platform, customer, product, compliance, expansion, board, and management-team claims to the release.
- Verifier support: the 2026-09-22 AM source reviewer cleared the item for drafting after the Yahoo Finance body exposed Business Wire release text supporting Phigenics, the strategic majority-growth investment from Battery Ventures, water-management positioning, and Battery’s partnership with management; no same-event local public post or draft was found.
9AT filing context
Public adviser/profile context reviewed by 9AT maps Battery Global Advisors, LLC / Battery Ventures to CIK 1582272, CRD 158508, SEC file 801-73308, and about $8.4 billion in ADV-reported profile scale. That context is broad Battery platform identity background only.
No 13F or Form 5500 context is included. Public-equity holdings and retirement-plan filings do not explain this private majority-growth investment, Phigenics’ water-management claims, customer outcomes, deal economics, ownership percentage, fund exposure, expected returns, or investment merit.
What to watch
Watch for later Battery, Phigenics, regulatory, financing-document, or company disclosures that clarify closing status, governance terms, participating vehicles, operating priorities, product investment, or expansion progress.
Future coverage should avoid converting source-party water-safety and compliance claims into 9AT claims. Product efficacy, public-health impact, customer growth, valuation, and fund-level exposure should stay tied to fresh public sources.